[Strategy of the French Society of Childhood Cancer (SFCE) for pediatric nodular lymphocyte predominant lymphoma].

[1]  I. Cree.  The WHO Classification of Haematolymphoid Tumours , 2022, Leukemia.

[2]  L. Staudt,et al.  The International Consensus Classification of Mature Lymphoid Neoplasms: A Report from the Clinical Advisory Committee. , 2022, Blood.

[3]  P. McKay,et al.  Management of children and adults with all stages of nodular lymphocyte predominant Hodgkin lymphoma — All StAGEs: A consensus‐based position paper from the Hodgkin lymphoma subgroup of the UK National Cancer Research Institute , 2022, British journal of haematology.

[4]  A. Engert,et al.  Current treatment options for nodular lymphocyte-predominant Hodgkin lymphoma , 2021, Current opinion in oncology.

[5]  A. Engert,et al.  How I treat nodular lymphocyte-predominant Hodgkin Lymphoma. , 2020, Blood.

[6]  V. Diehl,et al.  Long-Term Follow-Up of Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma Treated in the HD7 to HD15 Trials: A Report From the German Hodgkin Study Group. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  Alexandra G. Smith,et al.  Frontline management of nodular lymphocyte predominant Hodgkin lymphoma – a retrospective UK multicentre study , 2019, British journal of haematology.

[8]  A. Zelenetz,et al.  Active surveillance for nodular lymphocyte-predominant Hodgkin lymphoma. , 2019, Blood.

[9]  Michael L. Wang,et al.  Encouraging activity for R-CHOP in advanced stage nodular lymphocyte-predominant Hodgkin lymphoma. , 2017, Blood.

[10]  R. Bouabdallah,et al.  Rituximab‐ABV(D) for patients with Nodular lymphocyte predominant Hodgkin lymphoma ineligible for radiation therapy , 2016, British journal of haematology.

[11]  L. Constine,et al.  Minimal Treatment of Low-Risk, Pediatric Lymphocyte-Predominant Hodgkin Lymphoma: A Report From the Children's Oncology Group. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  A. Shankar,et al.  Relapsed or poorly responsive nodular lymphocyte predominant Hodgkin lymphoma in children and adolescents – a report from the United Kingdom's Children's Cancer and Leukaemia Study Group , 2016, British journal of haematology.

[13]  A. Stamatoullas,et al.  Nodular lymphocyte predominant Hodgkin lymphoma: a Lymphoma Study Association retrospective study , 2015, Haematologica.

[14]  A. Shankar,et al.  Childhood and Adolescent nodular lymphocyte predominant Hodgkin lymphoma ‐ A review of clinical outcome based on the histological variants , 2015, British journal of haematology.

[15]  R. Greil,et al.  Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin's lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial , 2015, The Lancet.

[16]  Bruce D Cheson,et al.  Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  R. Gascoyne,et al.  Advanced-stage nodular lymphocyte predominant Hodgkin lymphoma compared with classical Hodgkin lymphoma: a matched pair outcome analysis. , 2014, Blood.

[18]  D. Hasenclever,et al.  Treatment outcome after low intensity chemotherapy [CVP] in children and adolescents with early stage nodular lymphocyte predominant Hodgkin's lymphoma - an Anglo-French collaborative report. , 2012, European journal of cancer.

[19]  M. Hudson,et al.  Association between radiotherapy vs no radiotherapy based on early response to VAMP chemotherapy and survival among children with favorable-risk Hodgkin lymphoma. , 2012, JAMA.

[20]  K. Kelly,et al.  Long-term results of CCG 5942: a randomized comparison of chemotherapy with and without radiotherapy for children with Hodgkin's lymphoma--a report from the Children's Oncology Group. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  A. Whittemore,et al.  Second malignant neoplasms in survivors of pediatric Hodgkin's lymphoma treated with low-dose radiation and chemotherapy. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  A. Ng,et al.  Subsequent malignancies in children treated for Hodgkin's disease: associations with gender and radiation dose. , 2008, International journal of radiation oncology, biology, physics.

[23]  C. R. Pinkerton,et al.  Outcome of children with nodular lymphocyte predominant Hodgkin lymphoma – a Children's Cancer and Leukaemia Group report , 2007, British journal of haematology.

[24]  Robert Tibshirani,et al.  Characterization of Variant Patterns of Nodular Lymphocyte Predominant Hodgkin Lymphoma with Immunohistologic and Clinical Correlation , 2003, The American journal of surgical pathology.

[25]  G. Leverger,et al.  Lymphocyte-predominant Hodgkin's lymphoma in children: therapeutic abstention after initial lymph node resection--a Study of the French Society of Pediatric Oncology. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  M. Hudson,et al.  Lymphocyte-Predominant Hodgkin Disease in Children , 2002, Journal of pediatric hematology/oncology.

[27]  J. Armitage,et al.  Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  V. Diehl,et al.  Clinical presentation, course, and prognostic factors in lymphocyte-predominant Hodgkin's disease and lymphocyte-rich classical Hodgkin's disease: report from the European Task Force on Lymphoma Project on Lymphocyte-Predominant Hodgkin's Disease. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  F. Behm,et al.  Lymphocyte predominant Hodgkin disease: clinico-pathologic features and results of treatment--the Pediatric Oncology Group experience. , 1997, Medical and pediatric oncology.

[30]  G. Pinkus,et al.  Clinical presentation and outcome in lymphocyte-predominant Hodgkin's disease. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  T. Lister,et al.  Nodular type of lymphocyte predominant Hodgkin's disease. A clinical study of 50 cases. , 1995, Annals of oncology : official journal of the European Society for Medical Oncology.

[32]  R. Hoppe,et al.  Nodular and diffuse types of lymphocyte predominance Hodgkin's disease. , 1988, The New England journal of medicine.

[33]  Ronald C. Chen,et al.  Early-stage, lymphocyte-predominant Hodgkin's lymphoma: patient outcomes from a large, single-institution series with long follow-up. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.